AI and Software in Life Sciences

A curated newsletter covering the tools, platforms, and ideas shaping the digital transformation of life sciences.

By subscribing you agree to receive emails from Life Sciences Digital.

AI and Software in Life Sciences

A curated newsletter covering the tools, platforms, and ideas shaping the digital transformation of life sciences.

By subscribing you agree to receive emails from Life Sciences Digital.

What you'll find in the newsletter

Industry signals that matter

Analysis of the developments shaping digital life sciences — major partnerships, platform strategies, acquisitions, and technology shifts across biotech, pharma, and health tech.

The software layer of modern science

Updates on the tools, platforms, and infrastructure powering research, clinical development, and laboratory operations.

Tools and opportunities from the ecosystem

Selected software tools from the Life Sciences Digital database, along with relevant conferences, initiatives, and opportunities across the field.

Dive into our latest issues ↓

Insilico and Lilly Reset the Price of AI Drug Discovery. Oncology AI Enters the Clinical Standard.

Last week, the compute got installed. This week, the deals got signed. Insilico Medicine closed a $2.75 billion collaboration with Eli Lilly — $115 million upfront, exclusive worldwide license, multiple therapeutic areas — the largest capital commitment to an external AI drug discovery platform from a top-5 pharma to date. Caris Life Sciences launched an AI tool that guides first-line therapy selection for pancreatic cancer at the molecular level. The tool runs on tissue already collected for standard molecular profiling — no additional biopsy required. Tempus AI moved from data vendor to embedded development partner inside a Daiichi Sankyo drug program. And Merck confirmed 34,000 monthly users on its internal AI, with autonomous agents cutting commercial insight generation time in half. The question was never whether AI would reshape drug discovery. The question was who would pay for it, at what scale, and when. This week, Lilly answered all three.

Roche Locks In the Compute. IQVIA Deploys the Agents. Google Moves Into European Pharmacy.

Last week we tracked Veeva absorbing the compliance layer and IQVIA declaring 150 agents in production. This week, the infrastructure war got physical. Roche activated over 3,500 NVIDIA Blackwell GPUs across the U.S. and Europe — the largest declared AI compute footprint in pharma — and called it what it is: a factory. IQVIA launched IQVIA.ai at GTC 2026, an agentic platform already embedded in 19 of the top 20 pharmaceutical companies. Earendil Labs raised $787 million on an AI biologics platform that has already produced over 40 programs. And Google partnered with DocMorris to build an AI-first digital pharmacy for 11 million patients in Europe. The compute is being installed. The agents are running. The capital is following platforms that can prove output, not just potential.

Veeva Buys the Compliance Layer. Agentic AI Goes to Work. Life Sciences Software Is Choosing Its Infrastructure.

Last week we tracked Google Cloud threading itself through the infrastructure layer of American healthcare. This week, the decisions got more concrete. Veeva acquired the leading compliant conversational AI platform for patients and HCPs, signalling that AI-powered brand engagement is now a commercial requirement, not an experiment. IQVIA confirmed it has 150 AI agents running in production across its operations, with 500 targeted by 2027. Medidata launched a commercial AI companion that compresses clinical trial build timelines from weeks to hours. And NVIDIA committed $2 billion to the compute infrastructure that will run life sciences AI for the next decade. The platforms are being chosen. The infrastructure is being locked in. The window for "we are evaluating AI" is closing.

About us

Life Sciences Digital is a curated database of software tools used across biotechnology, pharmaceutical research, and related scientific fields.

The platform catalogs tools used in areas such as data analysis, laboratory automation, research collaboration, and digital infrastructure for life sciences organizations.

The goal is simple: make it easier to discover and understand the growing ecosystem of software supporting modern scientific work.

Browse life sciences tools →

Stay informed

Life sciences are becoming increasingly digital — from AI-driven research to the growing ecosystem of software used across laboratories, biotech, and pharma.

Our newsletter highlights the most relevant developments, tools, and industry signals shaping this shift.

Stay ahead.

By subscribing you agree to receive emails from Life Sciences Digital.